MTOR and acute myeloid leukemia: For example, in a mouse model of human acute myeloid leukemia (AML), Gnetin-C showed powerful anti-leukemia properties via inhibition of mTOR and MAPK kinases, two pathways that are aberrantly activated in AML cells [14].